From the Journals

Lab Markers May Guide Lupus Biologic Use

Analysis of 31 trials links serologic activity and disease severity to improved response.

Share

  • 1

    Meta-analysis included 31 trials with over 17,000 lupus patients.

  • 2

    Biologics improve clinical response in serologically active patients.

  • 3

    Anti-dsDNA antibodies and low complement levels are key predictors.

  • 4

    Baseline disease activity correlates with response.

  • 5

    B-cell activating factor therapies show consistent efficacy.

  • 6

    Biologics associated with modest adverse events reduction.

  • 7

    Herpes zoster rates were higher with biologics.

Original Source(s)

Lab Markers May Guide Lupus Biologic Use

  • by Olivia Anderson

  • March 19, 2026

Related Content

The Missing Step in Pediatric Lupus Care

Survey data show gaps between rheumatologists’ beliefs and clinical practice in screening and neuropsychological evaluation for childhood-onset systemic lupus erythematosus

Knee OA Trial Tests Diacerein

Researchers compared diacerein and placebo in a 24-week randomized study involving knee osteoarthritis with MRI-confirmed effusion-synovitis.

Dry Eye Across Autoimmune Diseases

The nationwide analysis found the highest rates of dry eye disease among patients with Sjögren’s syndrome.